Stay updated on Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial
Sign up to get notified when there's something new on the Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial page.

Latest updates to the Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial page
- ChecktodayChange DetectedRevision label updated from v3.4.3 to v3.5.0 on the page. No study data, eligibility criteria, or on-page guidance were changed.SummaryDifference0.0%

- Check7 days agoChange DetectedAdded revision: v3.4.3 and removed revision: v3.4.2.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check36 days agoChange DetectedRevision: v3.4.2 was added and the government funding status notice about a lapse in funding was removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check43 days agoChange DetectedA government funding/status notice was added indicating the NIH Clinical Center is open and updates regarding operating status. The page was updated to Revision: v3.4.1, replacing the previous v3.4.0 revision.SummaryDifference0.2%

- Check50 days agoChange DetectedAdded a glossary toggle and updated the page revision to v3.4.0. Capitalization of terms related to QC criteria and FEAR Act data has been standardized.SummaryDifference0.1%

- Check64 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

Stay in the know with updates to Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vemurafenib & Cobimetinib in BRAF V600E Craniopharyngioma Clinical Trial page.